AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) Releases Earnings Results, Beats Estimates By $0.06 EPS

Key Points

• Amneal Pharmaceuticals reported earnings of $0.23 per share for the quarter, exceeding the consensus estimate of $0.17 by $0.06.
• The stock has shown a significant market capitalization of $2.63 billion and a 52-week trading range from $6.59 to $9.48.
• Analysts maintain a generally positive outlook, with an average target price of $11.60 and several firms issuing buy ratings.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) released its quarterly earnings data on Tuesday. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.17 by $0.06, Zacks reports. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS updated its FY 2025 guidance to 0.700-0.750 EPS.

AMNEAL PHARMACEUTICALS Stock Up 4.0%

AMNEAL PHARMACEUTICALS stock traded up $0.33 during midday trading on Friday, hitting $8.54. The company's stock had a trading volume of 2,392,267 shares, compared to its average volume of 1,359,587. The stock's 50-day moving average price is $8.03 and its 200-day moving average price is $7.96. AMNEAL PHARMACEUTICALS has a 12 month low of $6.68 and a 12 month high of $9.48. The company has a market capitalization of $2.68 billion, a PE ratio of 854.85 and a beta of 1.11.

Institutional Investors Weigh In On AMNEAL PHARMACEUTICALS

Hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning grew its stake in AMNEAL PHARMACEUTICALS by 61.9% during the 2nd quarter. Creative Planning now owns 23,896 shares of the company's stock valued at $193,000 after acquiring an additional 9,136 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in AMNEAL PHARMACEUTICALS by 5.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company's stock worth $2,807,000 after purchasing an additional 16,536 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of AMNEAL PHARMACEUTICALS during the first quarter worth approximately $244,000. Millennium Management LLC lifted its holdings in shares of AMNEAL PHARMACEUTICALS by 32.6% during the first quarter. Millennium Management LLC now owns 2,087,398 shares of the company's stock worth $17,492,000 after buying an additional 512,842 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of AMNEAL PHARMACEUTICALS by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company's stock worth $793,000 after buying an additional 4,178 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on AMRX shares. The Goldman Sachs Group started coverage on AMNEAL PHARMACEUTICALS in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 target price on the stock. Wall Street Zen cut AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $11.60.

AMNEAL PHARMACEUTICALS Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.